Experience Matters.

Lawrence Blatt

Non-Executive Director

Co-founded Alios BioPharma, Inc., and led the company from inception to acquisition by Johnson & Johnson.

Iain D. Dukes

Venture Partner, OrbiMed

Holds multiple Board/CEO positions, alongside world-class licensing experience including at Merck & Co. and Amgen Inc.

Ron Hunt

Managing Director, New Leaf Venture Partners

Founder of New Leaf Venture Partners with over 20 years investment and company-building experience.

Richard N. Kender

Non-Executive Director

Involved in over 100 Business Development & Corporate Licensing transactions during 35 year tenure at Merck & Co.

Chau Q. Khuong

Non-Executive Director

Experienced investor focused on structured investments across private and public biopharmaceutical and medical device companies.

Dr. Ken Powell

Chairman

Founded and led Arrow Therapeutics Ltd to $150 million acquisition by AstraZeneca.

Alex C. Sapir

Chief Executive Officer

Grew small biotech start-up with upside to 150-person, publicly-traded company with approved, marketed product.

Raphaël Wisniewski

Partner, Andera Partners

Top pedigree investments, IPOs and trade sales over 19 years with Andera Partners.

Dr. Stuart Cockerill

Chief Scientific Officer, Founder

Spearheaded the GSK erbB2 Oncology Project Team that discovered Tykerb™ for metastatic breast cancer.

Dr. Rachel Harland

Head of Preclinical Development

Built value for two top-tier biotech companies via pivotal drug development strategies.

Dr. Eddy Littler

Chief Operating Officer

Led the identification and development of OlysioTM for chronic hepatitis C virus.

Dr. Neil Mathews

Project Director, Founder

Led deal-critical Hepatitis C project at Arrow Therapeutics prior to acquisition by AstraZeneca.

Alan A. Musso

Chief Financial Officer

Secured $150M financing and prepared Peloton Therapeutics for IPO — laying groundwork for Merck & Co. acquisition.

Alex C. Sapir

Chief Executive Officer

Grew small biotech start-up with upside to 150-person, publicly-traded company with approved, marketed product.

Dr. Elaine Thomas

Head of Virology

Advanced from Harvard Medical School post-doctoral fellowship to lead multiple preclinical & clinical virology studies.

Dr. Jason Zhou

CEO & Managing Director, CR-CP Life Science Fund

Pivotal role in high quality investment deals in GenesisCare and Genscript.

Dr. Ian Armstrong

Head of Formulation Development

Successfully led multiple formulation programs across all phases of the product development cycle.

Dr. Cora Griffin

Head of Business Development and Alliance Management

Successfully executed multiple deals in infectious diseases, ophthalmology and platforms.

Dr. Naveed Siddiqi

Senior Partner, Novo Holdings

Over 22 years of experience in life science venture investments, including multiple successful NASDAQ listings.

Dr. Brett Haumann

Chief Medical Officer

Spearheaded the successful development and approval of RELVAR®/BREO® for the treatment of asthma and COPD.

Jo Phillips

Head of Nonclinical Development and Project Management

Hugely experienced project manager with over 25 years in drug development roles.